Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.63 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 5/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17277362 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL17277533 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL16787789 | 0.91 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL1474821 | 0.90 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL17277334 | 0.88 | SSTR4 (0.48) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL17277590 | 0.83 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL12075488 | 0.83 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL12647108 | 0.82 | TLR4 (0.49) | NOS3NOS1NOS2 | |
| SCHEMBL3718507 | 0.82 | TLR4 (0.49) | NOS3NOS1NOS2 | |
| SCHEMBL9923476 | 0.82 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3KCNH2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | SLC6A2 3465/4885SLC6A4 4348/4885SLC6A3 4352/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | SLC6A2 3465/4885SLC6A4 4348/4885SLC6A3 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.